Patent ID: 7452870
Filing Date: 2008-11-18
Classification: A61K,A61P,C07H

Abstract:
1. A P2Y 12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y 12 receptor antagonist compound of general Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein a therapeutically effective amount of the compound is eluted to the local environment when the stent is placed in a vessel, wherein: X T m=0, 1 or 2; n=0 or 1; p=0, 1, or 2; where the sum of m+n+p is from 0 to 5; M=H, or a pharmaceutically-acceptable inorganic or organic counterion; D Y′=H, OH, or OR Z′=H, OH, or OR A=M, or A is a nucleoside residue which is defined as:  and which is linked to the phosphate chain via the 5′-position of the furanose or carbocycle; wherein: D Z=H, OH, or OR Y=H, OH, or OR  with the proviso that at least one of Y′, Z′, Y and Z is equal to OR R wherein: O is the corresponding 2′- and/or 3′-oxygen of the respective furanose or carbocycle; C is a carbon atom; R R R R R R wherein: the O atoms are the 2′- and 3′-oxygens of a furanose or carbocycle; and the 2′- and 3′-oxygens of the furanose or carbocycle are linked by a common carbon atom (C) to form a cyclical acetal, cyclical ketal, or cyclical orthoester; for cyclical acetals and ketals, R for cyclical orthoesters, R B and B′ are independently a purine residue, as in Formula IV, linked through the 9-position, or a pyrimidine residue, as in Formula V, linked through the 1-position; wherein: R R when R J is carbon or nitrogen, with the provision that when J=nitrogen, R R R R R R wherein NH is the amino residue at the C-6 position in a purine or the amino residue at the C-4 position in a pyrimidine; C is a carbon atom; W R R R